Participants had a mean age of 63.5 years, were 5.3 years on average past treatment, and were treated with surgery (59%), radiation (28%), surgery and radiation (11%) or treatment other than surgery and radiation (2%). Over 80% of participants reported any urinary incontinence and 43% experienced at least daily incontinence. The most common urinary incontinence symptoms were stress, post-void dribbling, urge and incontinence without awareness. Less common symptoms were nocturnal enuresis, mixed stress and urge, and continuous incontinence (see Table). Incontinence severity reported as the mean(SD) ICIQ score was 6.56(4.86) for the entire sample. Incontinence severity differed by cancer treatment (p<0.01). Patients treated with surgery & radiation had the highest ICIQ scores followed by surgery patients, radiation patients, and other treatment patients (see Table). Patients treated with surgery and radiation or surgery only were more likely to experience stress urinary incontinence (p<0.1) and insensible urinary incontinence incontinence (p<.01), while those treated with radiation only were more likely to experience urgency urinary incontinence (p<0.01). Urinary incontinence severity was associated with obesity (r=0.14, beta [95% CI] = 1.76 [0.51, 3.00]), poorer self-reported health (r=-0.25, beta [95% CI] = -0.08 [-0.11, -0.05]), and an increased number of co-morbidities (r=0.18, beta [95% CI] = 0.62 [0.28, 0.96]). Urinary incontinence severity was not associated with age (r=-0.03, beta [95% CI] = -0.02 [-0.09, 0.05]), race (r=-0.0001, beta [95% CI] = 0.001 [-1.41, 1.41]), Gleason score at diagnosis (r=0.02), prostate cancer stage at diagnosis (r=0.07), time since diagnosis (r=0.06, beta [95% CI] = 0.06 [-0.03, 0.16]) or time since treatment (r=0.03, beta [95% CI] = -0.33 [-1.28, 0.63]).